UNLABELLED: Growth hormone (GH) resistance has been associated with liver cirrhosis in humans but its contribution to the disease remains controversial. In order to elucidate whether GH resistance plays a causal role in the establishment and development of liver fibrosis, or rather represents a major consequence thereof, we challenged mice lacking the GH receptor gene (Ghr(-/-), a model for GH resistance) by crossing them with Mdr2 knockout mice (Mdr2(-/-)), a mouse model of inflammatory cholestasis and liver fibrosis. Ghr(-/-);Mdr2(-/-) mice showed elevated serum markers associated with liver damage and cholestasis, extensive bile duct proliferation, and increased collagen deposition relative to Mdr2(-/-) mice, thus suggesting a more severe liver fibrosis phenotype. Additionally, Ghr(-/-);Mdr2(-/-) mice had a pronounced down-regulation of hepatoprotective genes Hnf6, Egfr, and Igf-1, and significantly increased levels of reactive oxygen species (ROS) and apoptosis in hepatocytes, compared to control mice. Moreover, single knockout mice (Ghr(-/-)) fed with a diet containing 1% cholic acid displayed an increase in hepatocyte ROS production, hepatocyte apoptosis, and bile infarcts compared to their wild-type littermates, indicating that loss of Ghr renders hepatocytes more susceptible to toxic bile acid accumulation. Surprisingly, and despite their severe fibrotic phenotype, Ghr(-/-);Mdr2(-/-) mice displayed a significant decrease in tumor incidence compared to Mdr2(-/-) mice, indicating that loss of Ghr signaling may slow the progression from fibrosis/cirrhosis to cancer in the liver. CONCLUSION: GH resistance dramatically exacerbates liver fibrosis in a mouse model of inflammatory cholestasis, therefore suggesting that GH resistance plays a causal role in the disease and provides a novel target for the development of liver fibrosis treatments.
UNLABELLED: Growth hormone (GH) resistance has been associated with liver cirrhosis in humans but its contribution to the disease remains controversial. In order to elucidate whether GH resistance plays a causal role in the establishment and development of liver fibrosis, or rather represents a major consequence thereof, we challenged mice lacking the GH receptor gene (Ghr(-/-), a model for GH resistance) by crossing them with Mdr2 knockout mice (Mdr2(-/-)), a mouse model of inflammatory cholestasis and liver fibrosis. Ghr(-/-);Mdr2(-/-) mice showed elevated serum markers associated with liver damage and cholestasis, extensive bile duct proliferation, and increased collagen deposition relative to Mdr2(-/-) mice, thus suggesting a more severe liver fibrosis phenotype. Additionally, Ghr(-/-);Mdr2(-/-) mice had a pronounced down-regulation of hepatoprotective genes Hnf6, Egfr, and Igf-1, and significantly increased levels of reactive oxygen species (ROS) and apoptosis in hepatocytes, compared to control mice. Moreover, single knockout mice (Ghr(-/-)) fed with a diet containing 1% cholic acid displayed an increase in hepatocyte ROS production, hepatocyte apoptosis, and bile infarcts compared to their wild-type littermates, indicating that loss of Ghr renders hepatocytes more susceptible to toxic bile acid accumulation. Surprisingly, and despite their severe fibrotic phenotype, Ghr(-/-);Mdr2(-/-) mice displayed a significant decrease in tumor incidence compared to Mdr2(-/-) mice, indicating that loss of Ghr signaling may slow the progression from fibrosis/cirrhosis to cancer in the liver. CONCLUSION: GH resistance dramatically exacerbates liver fibrosis in a mouse model of inflammatory cholestasis, therefore suggesting that GH resistance plays a causal role in the disease and provides a novel target for the development of liver fibrosis treatments.
Authors: S Sanz; J B Pucilowska; S Liu; C M Rodríguez-Ortigosa; P K Lund; D A Brenner; C R Fuller; J G Simmons; A Pardo; M-L Martínez-Chantar; J A Fagin; J Prieto Journal: Gut Date: 2005-01 Impact factor: 23.059
Authors: Peter Fickert; Martin Wagner; Hanns-Ulrich Marschall; Andrea Fuchsbichler; Gernot Zollner; Oleksiy Tsybrovskyy; Kurt Zatloukal; Jie Liu; Michael P Waalkes; Cathleen Cover; Helmut Denk; Alan F Hofmann; Hartmut Jaeschke; Michael Trauner Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682
Authors: Lorena González; Ma Eugenia Díaz; Johanna G Miquet; Ana I Sotelo; Diego Fernández; Fernando P Dominici; Andrzej Bartke; Daniel Turyn Journal: J Endocrinol Date: 2009-12-23 Impact factor: 4.286
Authors: Alexander G Miethke; Wujuan Zhang; Julia Simmons; Amy E Taylor; Tiffany Shi; Shiva Kumar Shanmukhappa; Rebekah Karns; Shana White; Anil G Jegga; Celine S Lages; Stephenson Nkinin; Bradley T Keller; Kenneth D R Setchell Journal: Hepatology Date: 2015-08-21 Impact factor: 17.425
Authors: Edward O List; Darlene E Berryman; Mathew Buchman; Elizabeth A Jensen; Kevin Funk; Silvana Duran-Ortiz; Yanrong Qian; Jonathan A Young; Julie Slyby; Savannah McKenna; John J Kopchick Journal: Endocrinology Date: 2019-07-01 Impact factor: 4.736
Authors: Darlene E Berryman; Edward O List; Jonathan A Young; Mat Buchman; Silvana Duran-Ortiz; Colin Kruse; Stephen Bell; John J Kopchick Journal: Pituitary Date: 2021-01-12 Impact factor: 3.599